Japan· JP-3999450G2024
リサンキズマブ（遺伝子組換え）
A medicinal product containing リサンキズマブ（遺伝子組換え）, registered in Japan by アッヴィ, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- リサンキズマブ（遺伝子組換え）
- Manufacturer
- アッヴィ
- Country
- Japan (JP)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
リサンキズマブ（遺伝子組換え） in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesSkyriziAbbVie Inc.
- CzechiaSKYRIZIAbbVie Deutschland GmbH & Co.KG, Ludwigshafen
- FinlandSkyriziAbbVie Deutschland GmbH&Co.KG
- IrelandSkyrizi 150 mg Solution for injectionAbbVie Deutschland GmbH & Co. KG
- BelgiumSkyrizi 150 mgAbbVie Deutschland
- SwedenSkyrizi 150 mg Injektionsvätska, lösning i förfylld injektionspennaAbbVie Deutschland GmbH & Co KG
- IcelandSkyriziAbbVie Deutschland GmbH & Co. KG
- NetherlandsSkyrizi 150 mg, oplossing voor injectie in voorgevulde penAbbVie Deutschland GmbH & Co. KG
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Skyrizi
- Iceland · Skyrizi
- Liechtenstein · Skyrizi
- Norway · Skyrizi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b83e5f71-19cb-42b4-816a-dd37b56bba95 GET /v1/drugs/b83e5f71-19cb-42b4-816a-dd37b56bba95?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１５０ｍｇ１ｍＬ１筒",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "3999450G2024",
"category": "注射薬",
"price_yen": 474616,
"generic_name": "リサンキズマブ（遺伝子組換え）",
"product_name_jp": null,
"therapeutic_class": "3999",
"transitional_expiry": null
}See everything about リサンキズマブ（遺伝子組換え）.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.